{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:51Z","timestamp":1787026551311,"version":"build-2736575974"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is spreading worldwide, largely due to unhealthy lifestyles that contribute to the rise in diabetes, metabolic syndrome, and obesity. In this situation, the progression of injury to metabolic steatohepatitis can evolve to cirrhosis and, eventually, to hepatocellular carcinoma (HCC). It is well known that serine protease enzymes with different functions in cellular homeostasis act as signaling molecules that regulate liver inflammation by activating the protease-activated receptors (PARs) family members, expressed on the cellular plasma membrane. Among them, PAR2 plays a central role in the activation of signaling pathways in response to changes in the extracellular microenvironment. Experimental data have provided evidence that PAR2 is involved not only in inflammatory response but also in insulin resistance, lipid metabolism, and cancer. The major aims of this narrative review are addressed to assess PAR2 involvement in inflammation, metabolism, and liver disease progression and to explore possible therapeutic strategies, based on PAR2 inhibition, in order to prevent its biological effects in the context of MAFLD and cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1397441","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:25:07Z","timestamp":1728606307000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Protease activated receptor 2 as a novel druggable target for the treatment of metabolic dysfunction-associated fatty liver disease and cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Gianmarco","family":"Villano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pontisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024","article-title":"Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies","volume":"11","author":"Habibullah","year":"2024","journal-title":"Front Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol Aspects Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.00986.x","article-title":"Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma","volume":"42","author":"Yasui","year":"2012","journal-title":"Hepatol Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD -Implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.20.9208","article-title":"Molecular cloning of a potential proteinase activated receptor","volume":"91","author":"Nystedt","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-019-0194-8","article-title":"Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases","volume":"17","author":"Heuberger","year":"2019","journal-title":"Thromb J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature22309","article-title":"Structural insight into allosteric modulation of protease-activated receptor 2","volume":"545","author":"Cheng","year":"2017","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.01.003","article-title":"Structure, function and pathophysiology of protease activated receptors","volume":"130","author":"Adams","year":"2011","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/10409238.2020.1742090","article-title":"Protease propeptide structures, mechanisms of activation, and functions","volume":"55","author":"Boon","year":"2020","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nrm2299","article-title":"Heterotrimeric G protein activation by G-protein coupled receptors","volume":"9","author":"Oldham","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.7.4043","article-title":"Interactions of mast cell tryptase with thrombin receptors and PAR-2","volume":"272","author":"Molino","year":"1997","journal-title":"J Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: An emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1995.tb20784.x","article-title":"Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2","volume":"232","author":"Nystedt","year":"1995","journal-title":"Eur J Biochem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1124\/mol.104.006072","article-title":"Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking","volume":"67","author":"Stalheim","year":"2005","journal-title":"Mol Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5247.363","article-title":"Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization","volume":"271","author":"Ferguson","year":"1996","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2016.05.001","article-title":"Chapter one - ubiquitination and deubiquitination of G protein-coupled receptors","volume":"141","author":"Jean-Charles","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1476-5381.2010.00705.x","article-title":"Signal transduction by protease-activated receptors","volume":"160","author":"Soh","year":"2010","journal-title":"Br J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.201988","article-title":"Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2)","volume":"286","author":"Ramachandran","year":"2011","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2003-0025","article-title":"Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response","volume":"26","author":"Steinhoff","year":"2005","journal-title":"Endocr Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e99702","DOI":"10.1371\/journal.pone.0099702","article-title":"Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist","volume":"9","author":"Elmariah","year":"2014","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.599712","article-title":"Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4","volume":"289","author":"Zhao","year":"2014","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-427708","article-title":"Inflammation, obesity, and thrombosis","volume":"122","author":"Samad","year":"2013","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2461","article-title":"Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation","volume":"17","author":"Badeanlou","year":"2011","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-232702","article-title":"Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism","volume":"27","author":"Lim","year":"2013","journal-title":"FASEB J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.molmet.2019.08.019","article-title":"PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease","volume":"29","author":"Rana","year":"2019","journal-title":"Mol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00717","article-title":"Protease-activated receptors in the intestine: focus on inflammation and cancer","volume":"10","author":"S\u00e9bert","year":"2019","journal-title":"Front Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15332","article-title":"PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR","volume":"178","author":"Jiang","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666151209115232","article-title":"Protease-activated receptor 2: are common functions in glial and immune cells linked to inflammation-related CNS disorders","volume":"17","author":"Bushell","year":"2016","journal-title":"Curr Drug Targets"},{"key":"B32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrd3615","article-title":"Targeting proteinase-activated receptors: therapeutic potential and challenges","volume":"11","author":"Ramachandran","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.5315","article-title":"Protease-activated receptor 2 mediates eosinophil infiltrationand hyperreactivity in allergic inflammation of the airway","volume":"169","author":"Schmidlin","year":"2002","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1152\/physrev.00028.2003","article-title":"Protease-activated receptors: contribution to physiology and disease","volume":"84","author":"Ossovskaya","year":"2004","journal-title":"Physiol Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.12.108","article-title":"Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice","volume":"483","author":"Hayashi","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20170272","article-title":"Protease-activated receptor-2 promotes kidney tubular epithelial inflammation by inhibiting autophagy via the PI3K\/Akt\/mTOR signalling pathway","volume":"474","author":"Du","year":"2017","journal-title":"Biochem J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.615428","article-title":"PAR2 activation on human kidney tubular epithelial cells induces tissue factor synthesis, that enhances blood clotting","volume":"12","author":"Iyer","year":"2021","journal-title":"Front Physiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5007488","article-title":"Protease-activated receptor-2 and phospholipid metabolism analysis in hyperuricemia-induced renal injury","volume":"2023","author":"Sui","year":"2023","journal-title":"Mediators Inflamm"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/hh1301.092661","article-title":"Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists","volume":"89","author":"Hamilton","year":"2001","journal-title":"Circ Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00480","article-title":"Apixaban enhances vasodilatation mediated by protease-activated receptor 2 in isolated rat arteries","volume":"8","author":"Villari","year":"2017","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5273(96)02569-7","article-title":"Protease activated receptors modulate aortic vascular tone","author":"Magazine","year":"1996","journal-title":"Int J Cardiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704469","article-title":"Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles","volume":"135","author":"McGuire","year":"2002","journal-title":"Br J Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.093807","article-title":"Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation","volume":"316","author":"Kelso","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130336","article-title":"Protease-activated receptor 2: A novel pathogenic pathway in a murine model of osteoarthritis","volume":"69","author":"Ferrell","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200869","article-title":"Immunomodulatory role of proteinase-activated receptor-2","volume":"71","author":"Crilly","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2007.01.002","article-title":"The therapeutic potential of proteinase-activated receptors in arthritis","volume":"7","author":"McIntosh","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2102-9","article-title":"Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis","volume":"32","author":"Tindell","year":"2012","journal-title":"Rheumatol Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208268","article-title":"Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology","volume":"75","author":"Huesa","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00257","article-title":"Rheumatic disease: protease-activated receptor-2 in synovial joint pathobiology","volume":"9","author":"McCulloch","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/18223","article-title":"A protective role for protease-activated receptors in the airways","volume":"398","author":"Cocks","year":"1999","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.7.3577","article-title":"Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells","volume":"168","author":"Asokananthan","year":"2002","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2007.08.002","article-title":"Signal transduction for formation\/release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells","volume":"145","author":"Moriyuki","year":"2008","journal-title":"Regul Pept"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.12.051","article-title":"The protease-activated receptor2 (PAR2)-prostaglandin E2-prostanoid EP receptor axis: A potential bronchoprotective unit in the respiratory tract","volume":"533","author":"Henry","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.076232","article-title":"Protease activated receptor 2-mediated proliferation and collagen production of rat pancreatic stellate cells","volume":"312","author":"Masamune","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1038\/cddis.2016.357","article-title":"PAR2 regulates regeneration, transdifferentiation, and death","volume":"7","author":"Piran","year":"2016","journal-title":"Cell Death Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"116622","DOI":"10.1186\/s41232-024-00338-1","article-title":"Controlling autoimmune diabetes onset by targeting Protease-Activated Receptor 2","volume":"175","author":"Reches","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1254\/jjp.88.77","article-title":"Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear","volume":"88","author":"Kawagoe","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.133","article-title":"Epidermal barrier dysfunction in atopic dermatitis","volume":"129","author":"Cork","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64675-5","article-title":"Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign and Malignant human tissues","volume":"158","author":"D'Andrea","year":"2001","journal-title":"Am J Pathol"},{"key":"B61","first-page":"190","article-title":"Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes","volume":"109","author":"Wakita","year":"1997","journal-title":"Proc Assoc Am Physicians"},{"key":"B62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0023677215572841","article-title":"The concanavalin A model of acute hepatitis in mice","volume":"49","author":"Heymann","year":"2015","journal-title":"Lab Anim"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0023677215571192","article-title":"The carbon tetrachloride model in mice","volume":"49","author":"Scholten","year":"2015","journal-title":"Lab Anim"},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s41232-022-00238-2","article-title":"Resolving the conflicts around PAR2 opposing roles in regeneration by comparing immune-mediated and toxic-induced injuries","volume":"42","author":"Reches","year":"2022","journal-title":"Inflamm Regener"},{"key":"B65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41232-024-00338-1","article-title":"Par2-mediated responses in inflammation and regeneration: choosing between repair and damage","volume":"44","author":"Reches","year":"2024","journal-title":"Inflamm Regener"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R100057200","article-title":"Control of cholesterol turnover in the mouse","volume":"277","author":"Dietschy","year":"2002","journal-title":"Biol Chem"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.732743","article-title":"Targeting liver fibrosis with a cell-penetrating protease-activated receptor-2 (PAR2) pepducin","volume":"291","author":"Shearer","year":"2016","journal-title":"J Biol Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.14670\/HH-11-623","article-title":"Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases","volume":"30","author":"Novo","year":"2015","journal-title":"Histol Histopathol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31086","article-title":"Hepatic stellate cells induce an inflammatory phenotype in Kupffer cells via the release of extracellular vesicles","volume":"238","author":"Geng","year":"2023","journal-title":"J Cell Physiol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.25.14910","article-title":"The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor","volume":"271","author":"Nystedt","year":"1996","journal-title":"J Biol Chem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cells11152288","article-title":"Neutrophil elastase increases vascular permeability and leukocyte transmigration in cultured endothelial cells and obese mice","volume":"11","author":"Ushakumari","year":"2022","journal-title":"Cells"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2010.08.010","article-title":"JNK regulation of hepatic manifestations of the metabolic syndrome","volume":"21","author":"Czaja","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32589","article-title":"PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference","volume":"76","author":"Shearer","year":"2022","journal-title":"Hepatology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12859-023-05220-4","article-title":"Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma","volume":"24","author":"Yang","year":"2023","journal-title":"BMC Bioinf"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e2110","DOI":"10.1038\/cddis.2015.395","article-title":"Coagulation factor VII and Malignant progression of hepatocellular carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Cell Death Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143629","article-title":"Novel molecular targets for immune surveillance of hepatocellular carcinoma","volume":"15","author":"Guerra","year":"2023","journal-title":"Cancers"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21873\/anticanres.16782","article-title":"Proteinase-activated receptor 2: springboard of tumors","volume":"44","author":"Vetvicka","year":"2024","journal-title":"Anticancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1042\/BST20200191","article-title":"The development of proteinase-activated receptor-2 modulators and the challenges involved","volume":"48","author":"McIntosh","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101486","article-title":"1-Piperidine Propionic Acid as an allosteric inhibitor of Protease Activated Receptor-2","volume":"16","author":"Chinellato","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/324815","article-title":"CCAAT\/enhancer binding protein \u03b2 in relation to ER stress, inflammation and metabolic disturbances","volume":"2015","author":"van der Krieken","year":"2015","journal-title":"BioMed Res Int"},{"key":"B84","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10020-021-00283-6","article-title":"TGF-\u03b2-induced \u03b1-SMA expression is mediated by C\/EBP\u03b2 acetylation in human alveolar epithelial cells","volume":"27","author":"Ding","year":"2021","journal-title":"Mol Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101889","article-title":"The Protease Activated Receptor 2 - CCAAT\/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of Non-Alcoholic Steatohepatitis","volume":"81","author":"Villano","year":"2024","journal-title":"Mol Metab"},{"key":"B86","doi-asserted-by":"publisher","first-page":"22","DOI":"10.37349\/edd.2024.00038","article-title":"SERPINB3 in fibrogenic chronic liver diseases and primary liver cancers","volume":"3","author":"Pontisso","year":"2024","journal-title":"Explor Dig Dis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2016.09.005","article-title":"SERPINB3 and B4: from biochemistry to biology","volume":"62","author":"Sun","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2010.55","article-title":"SERPINB3 modulates TGF-\u03b2 expression in chronic liver disease","volume":"90","author":"Turato","year":"2010","journal-title":"Lab Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2011.1","article-title":"Overexpression of SERPIN B3 promotes epithelial proliferation and lung fibrosis in mice","volume":"91","author":"Lunardi","year":"2011","journal-title":"Lab Invest"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1038\/s41598-017-03744-3","article-title":"SerpinB3 promotes pro-fibrogenic responses in activated hepatic stellate cells","volume":"7","author":"Novo","year":"2017","journal-title":"Sci Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910526","article-title":"SerpinB3 as a pro-inflammatory mediator in the progression of experimental non-alcoholic fatty liver disease","volume":"13","author":"Novo","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2943","article-title":"Hypoxia up-regulates SERPINB3 through HIF-2\u03b1 in human liver cancer cells","volume":"6","author":"Cannito","year":"2015","journal-title":"Oncotarget"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29754","article-title":"Hypoxia inducible factor 2a drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein","volume":"67","author":"Morello","year":"2018","journal-title":"Hepatology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.10.002","article-title":"Hepatocyte-specific deletion of HIF2\u03b1 Prevents NASH-related liver carcinogenesis by decreasing cancer cell proliferation","volume":"13","author":"Foglia","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1397441\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:25:09Z","timestamp":1728606309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1397441\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":94,"alternative-id":["10.3389\/fimmu.2024.1397441"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1397441","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"article-number":"1397441"}}